Mechanisms of immune tolerance to allergens

Chemical Immunology and Allergy

Volumn 96, Issue , 2012, Pages 30-38

  Fujita, Hiroyuki ^a,b,c   Meyer, Norbert ^a   Akdis, Mübeccel ^a   Akdis, Cezmi A ^a,d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b CHRISTINE KÜHNE CENTER FOR ALLERGY RESEARCH AND EDUCATION CK CARE   (Switzerland)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; B LYMPHOCYTE ANTIGEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; B LYMPHOCYTE; BASOPHIL; CAT; CD4+ T LYMPHOCYTE; DENDRITIC CELL; EOSINOPHIL; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INNATE IMMUNITY; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; T LYMPHOCYTE; TRANSCELLULAR CELL MIGRATION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; IMMUNE RESPONSE; INFLAMMATORY CELL; MIGRATION; SUBLINGUAL IMMUNOTHERAPY; THYMUS;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INTERLEUKIN-10; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84859201753     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000331868     Document Type: Review

References (41)

1. Akdis CA, Akdis M: Mechanisms of allergenspecific immunotherapy. J Allergy Clin Immunol 2011;127:18-27, quiz 28-19.
2. Akdis M, Akdis CA: Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009;8:645-660.
3. Wang M, Takeda K, Shiraishi Y, Okamoto M, Dakhama A, Joetham A, Gelfand EW: Peanutinduced intestinal allergy is mediated through a mast cell-IgE-FC-epsilon-RI-IL-13 pathway. J Allergy Clin Immunol 2010;126:306-316, 316.e301-312.
4. Simons FE: Anaphylaxis. J Allergy Clin Immunol 2010;125:S161-S181.
5. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Quaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA: Interleukins, from 1 to 37, and interferongamma: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127:701-721.e1-70.
6. Solarewicz-Madejek K, Basinski TM, Crameri R, Akdis M, Akkaya A, Blaser K, Rabe KF, Akdis CA, Jutel M: T cells and eosinophils in bronchial smooth muscle cell death in asthma. Clin Exp Allergy 2009; 39:845-855.
7. Zimmermann M, Koreck A, Meyer N, Basinski T, Meiler F, Simone B, Woehrl S, Moritz K, Eiwegger T, Schmid-Grendelmeier P, Kemeny L, Akdis CA: TNF-like weak inducer of apoptosis (TWEAK) and TNF-alpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol 2011;127: 200-207, 207.e1-10.
8. Meyer N, Zimmermann M, Burgler S, Bassin C, Woehrl S, Moritz K, Rhyner C, Indermitte P, Schmid-Grendelmeier P, Akdis M, Menz G, Akdis CA: IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol 2010;125: 858-865.e10.
9. Akkoc T, de Koning PJ, Ruckert B, Barlan I, Akdis M, Akdis CA: Increased activation-induced cell death of high IFN-gamma-producing T(h)1 cells as a mechanism of T(h)2 predominance in atopic diseases. J Allergy Clin Immunol 2008;121:652-658.e1.
10. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA: Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010;40:1232-1240.
11. Akdis M, Akdis CA: Mechanisms of allergenspecific immunotherapy. J Allergy Clin Immunol 2007;119:780-791.
12. Fontenot JD, Gavin MA, Rudensky AY: FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-336.
13. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T, Sakaguchi S: FOXP3 controls regulatory T-cell function by interacting with Aml1/Runx1. Nature 2007; 446:685-689.
14. Klunker S, Chong MM, Mantel PY, Palomares O, Bassin C, Ziegler M, Ruckert B, Meiler F, Akdis M, Littman DR, Akdis CA: Transcription factors Runx1 and Runx3 in the induction and suppressive function of FOXP3+ inducible regulatory T cells. J Exp Med 2009;206:2701-2715.
15. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450: 566-569.
16. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37: 3021-3029.
17. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ, Vignali DA: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010;11:1093-1101.
18. Ke Y, Kapp JA: Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol 1996;156:916-921.
19. Chen W, Zhou D, Torrealba JR, Waddell TK, Grant D, Zhang L: Donor lymphocyte infusion induces long-term donor-specific cardiac xenograft survival through activation of recipient double-negative regulatory T cells. J Immunol 2005;175:3409-3416.
20. Deniz G, Erten G, Kucuksezer UC, Kocacik D, Karagiannidis C, Aktas E, Akdis CA, Akdis M: Regulatory NK cells suppress antigen-specific T cell responses. J Immunol 2008;180:850-857.
21. Fujita H, Teng A, Nozawa R, Takamoto-Matsui Y, Katagiri-Matsumura H, Ikezawa Z, Ishii Y: Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NKT cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model. J Immunol 2009;183:254-260.
22. Ishii Y, Nozawa R, Takamoto-Matsui Y, Teng A, Katagiri-Matsumura H, Nishikawa H, Fujita H, Tamura Y: Alpha-galactosylceramide-driven immunotherapy for allergy. Front Biosci 2008;13:6214-6228.
23. Lund FE, Randall TD: Effector and regulatory B cells: Modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10:236-247.
24. Fillatreau S, Gray D, Anderton SM: Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008;8:391-397.
25. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF: A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T celldependent inflammatory responses. Immunity 2008; 28:639-650.
26. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117:530-541.
27. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567-1575.
28. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M: In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205:2887-2898.
29. Jutel M, Akdis M, Akdis CA: Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009;39:1786-1800.
30. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R: Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: A population-based cross-sectional study. Lancet 2001; 357:752-756.
31. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M: Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and Toll-like receptors. Allergy 2008;63:1455-1463.
32. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, Viola A, Odom S, Rivera J, Colombo MP, Pucillo CE: CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008; 29:771-781.
33. Rak S, Hakanson L, Venge P: Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990;86:706-713.
34. Shim JY, Kim BS, Cho SH, Min KU, Hong SJ: Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy 2003;33:52-57.
35. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R: Long-term clinical efficacy in grass polleninduced rhinoconjunctivitis after treatment with SQstandardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131-138.1-7.
36. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS: Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009;124:150-156.e1-5.
37. Crameri R, Kundig TM, Akdis CA: Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:568-573.
38. Marcucci F, Incorvaia C, Sensi L, Di Cara G, Cadario G, Cavaliere A, Moingeon P, Puccinelli P, Di Gioacchino M, Frati F: Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol 2008;21:609-613.
39. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, Pitkin L, Pilette C, Nouri-Aria K, Durham SR: Sublingual grass pollen immunotherapy is associated with increases in sublingual FOXP3-expressing cells and elevated allergenspecific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010;40:598-606.
40. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G: Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-574, 574.e1-574.e7.
41. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wuthrich B, Crameri R, Graf N, Johansen P, Kundig TM: Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proc Natl Acad Sci USA 2008;105: 17908-17912.